NCT02620332

Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: King's College London · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Type 1 diabetes is an autoimmune disease in which the insulin secreting βcells of the pancreas are destroyed such that the patient is reliant on injection of insulin to adequately control blood glucose levels for the remainder of his/her life. The autoimmune process targets proteins in beta-cells which are termed autoantigens. This is a Phase 1 study using a novel investigational medicinal product (IMP) known as MultiPepT1De in a study of safety and tolerability of administration in patients with recent onset Type 1 diabetes. MultiPepT1De is a mixture of peptides from islet auto antigens. The mixture has been designed to induce or restore immunological tolerance to the beta-cell and thus control or limit autoimmunity to protect beta-cells

Detailed description

Recent onset type 1 diabetes patients will be randomized into 4 groups of 6 subjects and each group will receive 6 injections of either placebo, low, medium or high dose of IMP; each injection is intradermal and spaced 1 month apart.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
DRUG	MultiPepT1De injection	A mix of peptides
OTHER	Placebo	Water for injection

Timeline

• Start date: 2015-10-20
• Primary completion: 2017-07-31
• Completion: 2018-04-06
• First posted: 2015-12-03
• Last updated: 2019-08-14

Locations

1 site across 1 country: United Kingdom